S. Rahman, S. Al-Shibli, N. Amjad, Muna Khaleel Dheyab Al-Kubaisi, Norra Harun, Emad M. Nafie
{"title":"摘要:瘦素转导通路可能是治疗乳腺浸润性导管癌的靶点","authors":"S. Rahman, S. Al-Shibli, N. Amjad, Muna Khaleel Dheyab Al-Kubaisi, Norra Harun, Emad M. Nafie","doi":"10.1158/1535-7163.TARG-17-A198","DOIUrl":null,"url":null,"abstract":"Despite some controversies, it is generally suggested that obesity imparts a higher risk of breast cancer, the most common cancer among women all over the world. Since obese people usually have higher serum levels of leptin, a hormone secreted by white adipose tissue, the hormone is suspected as the link between adiposity and breast cancer. In this study we tried to explore a possible causal association of obesity and serum leptin with breast cancer by studying a sample of healthy controls and patients from Malaysian population. The control group comprised 40 women with negative mammogram for breast cancer, while the patient group comprised 51 women with invasive ductal carcinoma (IDC) of breast, who were going to be operated. We measured the common obesity parameters, confirmed the diagnosis of IDC of breast in the patients by standard histopathologic examination using hematoxylin and eosin stain, and estimated serum leptin levels using ELISA procedure. We estimated both pre- and postoperative samples of leptin from the patient group. Our results showed a highly significant difference in the serum leptin level between the control group and the patient group with a mean of 20.59 ± 14.4 ng/ml and 38.71 ± 12.2 ng/ml, respectively, having a P value of s = 0.598, P s = 0.217, P > 0.05). Our results suggest that compared to BMI, serum leptin has a much stronger association with IDC; since the source of high leptin in serum is not breast cancerous tissue, leptin cannot be a marker for IDC of breast; however, the hormone most likely is causally associated with the tumorigenesis of breast cancer. The results also indicate that obesity, as indicated by BMI, is weakly associated with IDC; however, broader studies with much larger sample sizes are needed to draw any definitive conclusion. We hypothesize that reducing leptin levels, blocking its downstream tissue specific signal transduction, and/or blocking the upstream leptin receptor pathway might help in the prevention and therapy of breast cancer. Citation Format: Shaikh M. Rahman, Saad M. Al-Shibli, Nasser M. Amjad, Muna K. Al-Kubaisi, Norra B. Harun, Emad M. Nafie. The leptin transduction pathway may be targeted against invasive ductal carcinoma of breast [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2017 Oct 26-30; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A198.","PeriodicalId":113643,"journal":{"name":"Hormonal Agents and Therapy","volume":"205 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Abstract A198: The leptin transduction pathway may be targeted against invasive ductal carcinoma of breast\",\"authors\":\"S. Rahman, S. Al-Shibli, N. Amjad, Muna Khaleel Dheyab Al-Kubaisi, Norra Harun, Emad M. Nafie\",\"doi\":\"10.1158/1535-7163.TARG-17-A198\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Despite some controversies, it is generally suggested that obesity imparts a higher risk of breast cancer, the most common cancer among women all over the world. Since obese people usually have higher serum levels of leptin, a hormone secreted by white adipose tissue, the hormone is suspected as the link between adiposity and breast cancer. In this study we tried to explore a possible causal association of obesity and serum leptin with breast cancer by studying a sample of healthy controls and patients from Malaysian population. The control group comprised 40 women with negative mammogram for breast cancer, while the patient group comprised 51 women with invasive ductal carcinoma (IDC) of breast, who were going to be operated. We measured the common obesity parameters, confirmed the diagnosis of IDC of breast in the patients by standard histopathologic examination using hematoxylin and eosin stain, and estimated serum leptin levels using ELISA procedure. We estimated both pre- and postoperative samples of leptin from the patient group. Our results showed a highly significant difference in the serum leptin level between the control group and the patient group with a mean of 20.59 ± 14.4 ng/ml and 38.71 ± 12.2 ng/ml, respectively, having a P value of s = 0.598, P s = 0.217, P > 0.05). Our results suggest that compared to BMI, serum leptin has a much stronger association with IDC; since the source of high leptin in serum is not breast cancerous tissue, leptin cannot be a marker for IDC of breast; however, the hormone most likely is causally associated with the tumorigenesis of breast cancer. The results also indicate that obesity, as indicated by BMI, is weakly associated with IDC; however, broader studies with much larger sample sizes are needed to draw any definitive conclusion. We hypothesize that reducing leptin levels, blocking its downstream tissue specific signal transduction, and/or blocking the upstream leptin receptor pathway might help in the prevention and therapy of breast cancer. Citation Format: Shaikh M. Rahman, Saad M. Al-Shibli, Nasser M. Amjad, Muna K. Al-Kubaisi, Norra B. Harun, Emad M. Nafie. The leptin transduction pathway may be targeted against invasive ductal carcinoma of breast [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2017 Oct 26-30; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A198.\",\"PeriodicalId\":113643,\"journal\":{\"name\":\"Hormonal Agents and Therapy\",\"volume\":\"205 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hormonal Agents and Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1158/1535-7163.TARG-17-A198\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hormonal Agents and Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/1535-7163.TARG-17-A198","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
尽管存在一些争议,但人们普遍认为,肥胖会增加患乳腺癌的风险,乳腺癌是全世界女性中最常见的癌症。由于肥胖的人通常有较高的血清瘦素水平,一种由白色脂肪组织分泌的激素,这种激素被怀疑是肥胖和乳腺癌之间的联系。在这项研究中,我们试图通过研究来自马来西亚人口的健康对照和患者样本来探索肥胖和血清瘦素与乳腺癌之间可能的因果关系。对照组为40例乳腺x光检查阴性的女性,患者组为51例乳腺浸润性导管癌(invasive ductal carcinoma, IDC)拟行手术治疗的女性。我们测量了常见的肥胖参数,通过苏木精和伊红染色的标准组织病理学检查证实了患者乳腺IDC的诊断,并使用ELISA方法估计了血清瘦素水平。我们对患者组的术前和术后瘦素样本进行了估计。结果显示,对照组和患者组血清瘦素水平差异极显著,分别为20.59±14.4 ng/ml和38.71±12.2 ng/ml, P值分别为s = 0.598、P = 0.217, P > 0.05。我们的研究结果表明,与BMI相比,血清瘦素与IDC的相关性要强得多;由于血清中高瘦素的来源不是乳腺癌组织,因此不能作为乳腺癌IDC的标志;然而,这种激素很可能与乳腺癌的肿瘤发生有因果关系。结果还表明,肥胖(如BMI所示)与IDC的相关性较弱;然而,要得出任何明确的结论,需要更广泛的研究,样本量要大得多。我们假设降低瘦素水平,阻断其下游组织特异性信号转导,和/或阻断上游瘦素受体通路可能有助于预防和治疗乳腺癌。引文格式:Shaikh M. Rahman, Saad M. Al-Shibli, Nasser M. Amjad, Muna K. Al-Kubaisi, Norra B. Harun, Emad M. Nafie瘦素转导通路可能是治疗乳腺浸润性导管癌的靶点[摘要]。摘自:AACR-NCI-EORTC国际会议论文集:分子靶点和癌症治疗;2017年10月26-30日;费城,宾夕法尼亚州。费城(PA): AACR;中华肿瘤杂志,2018;17(1增刊):1a198。
Abstract A198: The leptin transduction pathway may be targeted against invasive ductal carcinoma of breast
Despite some controversies, it is generally suggested that obesity imparts a higher risk of breast cancer, the most common cancer among women all over the world. Since obese people usually have higher serum levels of leptin, a hormone secreted by white adipose tissue, the hormone is suspected as the link between adiposity and breast cancer. In this study we tried to explore a possible causal association of obesity and serum leptin with breast cancer by studying a sample of healthy controls and patients from Malaysian population. The control group comprised 40 women with negative mammogram for breast cancer, while the patient group comprised 51 women with invasive ductal carcinoma (IDC) of breast, who were going to be operated. We measured the common obesity parameters, confirmed the diagnosis of IDC of breast in the patients by standard histopathologic examination using hematoxylin and eosin stain, and estimated serum leptin levels using ELISA procedure. We estimated both pre- and postoperative samples of leptin from the patient group. Our results showed a highly significant difference in the serum leptin level between the control group and the patient group with a mean of 20.59 ± 14.4 ng/ml and 38.71 ± 12.2 ng/ml, respectively, having a P value of s = 0.598, P s = 0.217, P > 0.05). Our results suggest that compared to BMI, serum leptin has a much stronger association with IDC; since the source of high leptin in serum is not breast cancerous tissue, leptin cannot be a marker for IDC of breast; however, the hormone most likely is causally associated with the tumorigenesis of breast cancer. The results also indicate that obesity, as indicated by BMI, is weakly associated with IDC; however, broader studies with much larger sample sizes are needed to draw any definitive conclusion. We hypothesize that reducing leptin levels, blocking its downstream tissue specific signal transduction, and/or blocking the upstream leptin receptor pathway might help in the prevention and therapy of breast cancer. Citation Format: Shaikh M. Rahman, Saad M. Al-Shibli, Nasser M. Amjad, Muna K. Al-Kubaisi, Norra B. Harun, Emad M. Nafie. The leptin transduction pathway may be targeted against invasive ductal carcinoma of breast [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2017 Oct 26-30; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A198.